Flying high: Airline stocks set to soar in 2023
Marc Kennis, December 9, 2022
We like airline stocks
Our own Stuart Roberts featured on AusBiz to put airline stocks in focus, mentioning that 2023 could be a rip-roaring year for the sector as travel ramps up and Australians continue chomping at the bit to jump on a plane and fly out for vacations and business trips.
The airline sector is recovering
A recent report from IATA shows that airlines could collectively be in profit in 2023, for the first time since 2019. 2024 is the big year, because if margins are anything like 2019, then profits could possible be five times as big.
Air New Zealand just upgraded its guidance
Air New Zealand (ASX:AIZ) has upgraded its earnings guidance this week, pointing to positive signs that the next couple of years are going to be huge travel years. Stocks have only just started to respond to the burgeoning increase in travel bookings, activity, upgraded earnings guidances and revenue. Lower oil prices that fuel planes, jets and engines now can keep this airline boom going for a while yet.
Stuart also mentions that it’s critical to watch how airline stocks, including Qantas (ASX:QAN), perform on local and international markets once they get back into full practice and capacity in the new year.
No time to do stock research, but you still want to invest?
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
No credit card needed and the trial expires automatically.
Blog Categories
Get Our Top 5 ASX Stocks for FY25
Recent Posts
Can Gold Hit $4,000 in 2025? These 5 ASX Stocks Could Soar if It Does
In our view, the question isn’t just whether gold can hit $4,000 an ounce in 2025; it’s about what happens…
Qantas Board Shake-Up: Is Investor Pressure Finally Taking Effect?
Qantas Airways, Australia’s flagship airline, has long been a symbol of national pride, maintaining a central position in the country’s…
Orthocell (ASX:OCC): All systems go for a US market roll out of its flagship Remplir nerve repair product
Orthocell (ASX:OCC) is the latest ASX biotech to obtain FDA approval. Its nerve repair product Remplir was already approved in…